vs

Side-by-side financial comparison of Ametek (AME) and Solventum (SOLV). Click either name above to swap in a different company.

Ametek is the larger business by last-quarter revenue ($2.0B vs $2.0B, roughly 1.0× Solventum). Ametek runs the higher net margin — 19.9% vs 3.2%, a 16.8% gap on every dollar of revenue. On growth, Ametek posted the faster year-over-year revenue change (13.4% vs -3.7%). Ametek produced more free cash flow last quarter ($527.3M vs $32.0M). Over the past eight quarters, Ametek's revenue compounded faster (7.3% CAGR vs -0.4%).

AMETEK, Inc. is an American multinational conglomerate and global designer and manufacturer of electronic instruments and electromechanical devices with headquarters in the United States and over 150 sites worldwide.

Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024.

AME vs SOLV — Head-to-Head

Bigger by revenue
AME
AME
1.0× larger
AME
$2.0B
$2.0B
SOLV
Growing faster (revenue YoY)
AME
AME
+17.2% gap
AME
13.4%
-3.7%
SOLV
Higher net margin
AME
AME
16.8% more per $
AME
19.9%
3.2%
SOLV
More free cash flow
AME
AME
$495.3M more FCF
AME
$527.3M
$32.0M
SOLV
Faster 2-yr revenue CAGR
AME
AME
Annualised
AME
7.3%
-0.4%
SOLV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AME
AME
SOLV
SOLV
Revenue
$2.0B
$2.0B
Net Profit
$398.6M
$63.0M
Gross Margin
36.0%
51.4%
Operating Margin
25.3%
6.3%
Net Margin
19.9%
3.2%
Revenue YoY
13.4%
-3.7%
Net Profit YoY
2.9%
103.2%
EPS (diluted)
$1.73
$0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AME
AME
SOLV
SOLV
Q4 25
$2.0B
$2.0B
Q3 25
$1.9B
$2.1B
Q2 25
$1.8B
$2.2B
Q1 25
$1.7B
$2.1B
Q4 24
$1.8B
$2.1B
Q3 24
$1.7B
$2.1B
Q2 24
$1.7B
$2.1B
Q1 24
$1.7B
$2.0B
Net Profit
AME
AME
SOLV
SOLV
Q4 25
$398.6M
$63.0M
Q3 25
$371.4M
$1.3B
Q2 25
$358.4M
$90.0M
Q1 25
$351.8M
$137.0M
Q4 24
$387.3M
$31.0M
Q3 24
$340.2M
$122.0M
Q2 24
$337.7M
$89.0M
Q1 24
$310.9M
$237.0M
Gross Margin
AME
AME
SOLV
SOLV
Q4 25
36.0%
51.4%
Q3 25
36.3%
54.2%
Q2 25
35.8%
54.4%
Q1 25
36.1%
53.8%
Q4 24
36.6%
53.9%
Q3 24
36.0%
56.0%
Q2 24
36.0%
54.6%
Q1 24
34.1%
58.1%
Operating Margin
AME
AME
SOLV
SOLV
Q4 25
25.3%
6.3%
Q3 25
25.8%
80.6%
Q2 25
26.0%
9.9%
Q1 25
26.3%
7.3%
Q4 24
26.6%
6.6%
Q3 24
26.1%
13.2%
Q2 24
25.8%
11.7%
Q1 24
24.0%
18.9%
Net Margin
AME
AME
SOLV
SOLV
Q4 25
19.9%
3.2%
Q3 25
19.6%
60.4%
Q2 25
20.2%
4.2%
Q1 25
20.3%
6.6%
Q4 24
22.0%
1.5%
Q3 24
19.9%
5.9%
Q2 24
19.5%
4.3%
Q1 24
17.9%
11.8%
EPS (diluted)
AME
AME
SOLV
SOLV
Q4 25
$1.73
$0.37
Q3 25
$1.60
$7.22
Q2 25
$1.55
$0.51
Q1 25
$1.52
$0.78
Q4 24
$1.67
$0.18
Q3 24
$1.47
$0.70
Q2 24
$1.45
$0.51
Q1 24
$1.34
$1.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AME
AME
SOLV
SOLV
Cash + ST InvestmentsLiquidity on hand
$458.0M
$878.0M
Total DebtLower is stronger
$2.3B
$5.0B
Stockholders' EquityBook value
$10.6B
$5.0B
Total Assets
$16.1B
$14.3B
Debt / EquityLower = less leverage
0.21×
1.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AME
AME
SOLV
SOLV
Q4 25
$458.0M
$878.0M
Q3 25
$439.2M
$1.6B
Q2 25
$619.7M
$492.0M
Q1 25
$399.0M
$534.0M
Q4 24
$374.0M
$762.0M
Q3 24
$396.3M
$772.0M
Q2 24
$396.6M
$897.0M
Q1 24
$373.8M
$996.0M
Total Debt
AME
AME
SOLV
SOLV
Q4 25
$2.3B
$5.0B
Q3 25
$5.1B
Q2 25
$7.8B
Q1 25
$7.9B
Q4 24
$2.1B
$8.0B
Q3 24
$8.1B
Q2 24
$8.3B
Q1 24
$8.3B
Stockholders' Equity
AME
AME
SOLV
SOLV
Q4 25
$10.6B
$5.0B
Q3 25
$10.5B
$5.0B
Q2 25
$10.4B
$3.6B
Q1 25
$10.0B
$3.3B
Q4 24
$9.7B
$3.0B
Q3 24
$9.6B
$3.2B
Q2 24
$9.3B
$2.9B
Q1 24
$9.0B
$3.9B
Total Assets
AME
AME
SOLV
SOLV
Q4 25
$16.1B
$14.3B
Q3 25
$16.2B
$14.0B
Q2 25
$15.3B
$15.1B
Q1 25
$14.9B
$14.5B
Q4 24
$14.6B
$14.5B
Q3 24
$14.8B
$14.7B
Q2 24
$14.8B
$14.6B
Q1 24
$14.9B
$14.7B
Debt / Equity
AME
AME
SOLV
SOLV
Q4 25
0.21×
1.00×
Q3 25
1.03×
Q2 25
2.14×
Q1 25
2.43×
Q4 24
0.22×
2.71×
Q3 24
2.54×
Q2 24
2.90×
Q1 24
2.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AME
AME
SOLV
SOLV
Operating Cash FlowLast quarter
$584.3M
$95.0M
Free Cash FlowOCF − Capex
$527.3M
$32.0M
FCF MarginFCF / Revenue
26.4%
1.6%
Capex IntensityCapex / Revenue
2.9%
3.2%
Cash ConversionOCF / Net Profit
1.47×
1.51×
TTM Free Cash FlowTrailing 4 quarters
$1.7B
$-10.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AME
AME
SOLV
SOLV
Q4 25
$584.3M
$95.0M
Q3 25
$440.9M
$76.0M
Q2 25
$359.1M
$169.0M
Q1 25
$417.5M
$29.0M
Q4 24
$550.0M
$219.0M
Q3 24
$487.2M
$169.0M
Q2 24
$381.4M
$355.0M
Q1 24
$410.2M
$442.0M
Free Cash Flow
AME
AME
SOLV
SOLV
Q4 25
$527.3M
$32.0M
Q3 25
$420.0M
$-21.0M
Q2 25
$329.8M
$59.0M
Q1 25
$394.5M
$-80.0M
Q4 24
$498.3M
$92.0M
Q3 24
$460.9M
$76.0M
Q2 24
$360.0M
$297.0M
Q1 24
$382.6M
$340.0M
FCF Margin
AME
AME
SOLV
SOLV
Q4 25
26.4%
1.6%
Q3 25
22.2%
-1.0%
Q2 25
18.5%
2.7%
Q1 25
22.8%
-3.9%
Q4 24
28.3%
4.4%
Q3 24
27.0%
3.7%
Q2 24
20.8%
14.3%
Q1 24
22.0%
16.9%
Capex Intensity
AME
AME
SOLV
SOLV
Q4 25
2.9%
3.2%
Q3 25
1.1%
4.6%
Q2 25
1.6%
5.1%
Q1 25
1.3%
5.3%
Q4 24
2.9%
6.1%
Q3 24
1.5%
4.5%
Q2 24
1.2%
2.8%
Q1 24
1.6%
5.1%
Cash Conversion
AME
AME
SOLV
SOLV
Q4 25
1.47×
1.51×
Q3 25
1.19×
0.06×
Q2 25
1.00×
1.88×
Q1 25
1.19×
0.21×
Q4 24
1.42×
7.06×
Q3 24
1.43×
1.39×
Q2 24
1.13×
3.99×
Q1 24
1.32×
1.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AME
AME

Transferred At Point In Time$1.1B54%
Electronic Instruments Group$620.1M31%
Transferred Over Time$294.6M15%

SOLV
SOLV

Infection Prevention And Surgical Solutions$752.0M38%
Cost Of Software And Rentals$508.0M25%
Health Information Systems Segment$347.0M17%
Dental Solutions Segment$343.0M17%
Related Party$14.0M1%

Related Comparisons